Lexaria Bioscience (LEXX) Non Operating Income (2022 - 2026)

Lexaria Bioscience has disclosed Non Operating Income across 5 years of filings, most recently posting $1769.0 for Q1 2026.

• Non Operating Income for Q1 2026 came in at $1769.0, down 94.8% year-over-year; the trailing twelve-month figure through Feb 2026 was -$69128.0 (down 919.44% YoY), and the FY2025 annual result was -$30697.0, up 44.71% from the prior year.
• Non Operating Income came in at $1769.0 for Q1 2026 at Lexaria Bioscience, up from -$22081.0 in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $34040.0 in Q1 2025 to a low of -$134902.0 in Q3 2023.
• The 5-year median for Non Operating Income is -$12276.0 (2024), against an average of -$20359.7.
• Across the five-year window, Non Operating Income plunged 339.28% in 2024 and jumped 122.89% in 2025, its largest moves.
• Lexaria Bioscience's Non Operating Income stood at -$73887.0 in 2022, then soared by 37.88% to -$45896.0 in 2023, then soared by 65.31% to -$15921.0 in 2024, then sank by 38.69% to -$22081.0 in 2025, then soared by 108.01% to $1769.0 in 2026.
• The last three Non Operating Income figures came in at $1769.0 (Q1 2026), -$22081.0 (Q4 2025), and -$8631.0 (Q3 2025), per Business Quant data.